Bayer, Chattem Sneeze At NAD Decision On Claritin And Nasacort Comparison
This article was originally published in The Tan Sheet
NAD’s review of Bayer’s Claritin and Claritin-D ads upsets Bayer and challenger Chattem as both appeal the decision to the National Advertising Review Board. Bayer argues it supports the claim nothing “works faster” than Claritin-D, while Chattem says Bayer does not support claiming Claritin-D “starts to work on allergies in 30 minutes.”
You may also be interested in...
“Strong scientific consensus with regard to product efficacy” justifies claims that Sanofi’s Nasacort Allergy 24HR is “the most effective OTC medicine for the treatment of nasal allergy symptoms,” NAD determines. Claritin-maker Merck, in its challenge, argued Sanofi needs head-to-head testing to support the claim.
The National Advertising Division upholds Sanofi’s claims its Allegra antihistamine is “proven effective even at 8x high pollen levels.”
FTC files complaint against Quickwork as first action under authority granted in the COVID-19 Consumer Protection Act. The enforcement came after the firm twice ingored warnings to discontinue claims its vitamin D and zinc supplements were equal to or more effective than current vaccines.